Evidence map›Paper›PMID 33804126›Full record

ArticleAntioxidants (Basel, Switzerland)2021

CTLA-2 Alpha Is a Potent Inhibitor of Angiogenesis in Murine Ocular Tissue.

Kazuichi Maruyama, Kazuhito Yoneda, Sunao Sugita, Yoshimi Yamamoto, Masato Koike, Christoph Peters, Yasuo Uchiyama, Kohji Nishida

Open access · goldAbstract read
In one paragraph

Article in Antioxidants (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 2 countries.

Kazuichi MaruyamaDepartment of Vision Informatics, Osaka University Graduate School of Medicine, Suita 565-0871, Japan.ORCID 0000-0001-6283-5466
Kazuhito YonedaDepartment of Ophthalmology, Kyoto Prefectural University Graduate School of Medicine, Kyoto 602-0841, Japan.
Sunao SugitaRIKEN Center for Development Biology, Kobe 650-0047, Japan.
Yoshimi YamamotoLaboratory of Biochemistry and Radiation Biology, Department of Veterinary Science, Faculty of Agriculture, Yamaguchi University, Yamaguchi 753-8511, Japan.
Masato KoikeDepartment of Cell Biology and Neuroscience, Juntendo University Graduate School of Medicine, Tokyo 113-8421, Japan.
Christoph PetersInstitute of Molecular Medicine and Cell Research, University of Freiburg, 79098 Freiburg, Germany.
Yasuo UchiyamaDepartment of Cellular and Molecular Neuropathology, Juntendo University Graduate School of Medicine, Tokyo 113-8421, Japan.
Kohji NishidaIntegrated Frontier Research for Medical Science Division, Institute for Open and Transdisciplinary Research Initiatives (OTRI), Osaka University, Osaka 565-0871, Japan.
Juntendo University · JPThe University of Osaka · JPKyoto Prefectural University · JPUniversity of Freiburg · DEYamaguchi University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cytotoxic T lymphocyte antigen-2 (CTLA-2) alpha has been reported to suppress the activities of cathepsin L (Cath L), which is deeply involved in angiogenesis. Therefore, we assessed whether CTLA-2 alpha plays a role in angiogenesis in ocular tissue. To establish models of corneal inflammation and experimental choroidal neovascularization (CNV), male C57BL/6J mice (

Indexed as

angiogenesischoroidal neovascularizationcorneal inflammationcytotoxic T lymphocyte antigen-2 alpha

Identifiers

PMID33804126
PMCPMC8000157
OpenAlexW3139001128

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.